Semax and selank on TikTok: separating hype from human data

What did @redheadedpepchild actually say?

The creator says she takes both selank and semax regularly, and that skipping them for a few days causes noticeable mood drops and brain fog. She uses selank primarily for what she calls "neuroprotection" and mood regulation, and semax Monday through Friday for work focus. She has self-diagnosed ADHD and suspects she may be on the autism spectrum.

She also explicitly says she has mild depression but no therapist, and credits selank with making her "life in general got so much less painful to go through emotions." For semax, she values that it "takes away the brain fog" without the jittery feeling she got from Adderall. Her framing throughout is personal experience, not medical authority, which is worth noting before we get into the science.

Does the science back this up?

There is genuine preliminary research on both compounds, but calling it robust would be a stretch. Most of it comes from Russian clinical trials, which have significant methodological limitations.

Selank is a synthetic heptapeptide developed in Russia, derived from tuftsin. A 2001 study by Semenova et al. in Eksperimental'naia i Klinicheskaia Farmakologiia reported anxiolytic effects in human subjects with generalized anxiety disorder, with effects described as comparable to benzodiazepines but without sedation or dependence markers. That is a meaningful finding if the methodology holds up, and some of it does. Selank appears to modulate GABA-A receptors and influence BDNF expression, which would mechanistically support mood-stabilizing effects.

Semax has more published data. Dolotov et al. (2006, Journal of Molecular Neuroscience) found that semax increases BDNF and NGF in rat hippocampus and frontal cortex. Russian clinical use for stroke recovery and attention deficits has been documented, though the trial designs would not pass FDA scrutiny. A 2021 review by Eremin et al. in Behavioural Brain Research surveyed the cognitive effects literature and found consistent but modest pro-cognitive signals. None of these studies are double-blind placebo-controlled trials in ADHD populations in the US.

What did they get wrong (or right)?

She got the basic mechanism framing mostly right. Selank does have anxiolytic properties with some scientific support, and semax does appear to influence cognitive function through neurotrophic pathways. Calling selank a mood stabilizer in casual terms is a reasonable simplification.

What she gets wrong, or at least overreaches on, is the confidence of her self-dosing for undiagnosed psychiatric conditions. She says she has "ADHD self diagnosed" and "may be on the autism spectrum." Using unregulated, non-FDA-approved peptides as a substitute for evaluated psychiatric treatment is a real problem, not just a legal technicality. If she does have ADHD or an anxiety disorder, a clinician could offer treatments with established safety profiles and actual dosing data in those populations.

Her description of mood dropping "after a few days" without selank is plausible, but it could also reflect expectation effects or the natural fluctuation of perimenopausal hormones she herself mentions. She acknowledges this uncertainty, which is honest. However, presenting that as evidence the peptide is working is a logical gap.

She also calls these peptides "non-stimulant" as if that means automatically safer. Non-stimulant does not mean low-risk.

What should you actually know?

Neither selank nor semax is FDA-approved. Both are available in the US primarily as research chemicals or through compounding pharmacies. The compounds are not equivalent across sources, and purity and dosing accuracy in non-regulated products vary significantly. This is not a theoretical concern. A 2020 analysis published in JAMA on compounded medications broadly found frequent potency deviations.

If you are dealing with mood issues, depression, perimenopausal symptoms, or suspected ADHD, those are clinical problems. Telehealth access for mental health has expanded substantially, including low-cost and sliding scale options that did not exist a few years ago. That is not a dismissal of her experience with these peptides. It is a reminder that self-treating psychiatric symptoms with unregulated compounds while avoiding professional evaluation carries real risk.

The existing science on selank and semax is genuinely interesting. It is not mature enough to guide confident personal dosing decisions for complex neuropsychiatric presentations.